Aduro Announces Changes to its Board of Directors
February 21 2019 - 7:00AM
Aduro Biotech, Inc. (NASDAQ: ADRO) today announced the appointment
of David H. Mack, Ph.D., President and CEO of PMV Pharmaceuticals,
to its Board of Directors effective February 19, 2019. In addition,
Frank McCormick, Ph.D., F.R.S., a director since Aduro’s inception,
will transition off the company’s Board and to the company’s
Scientific Advisory Board.
“As we advance our first-in-class STING and APRIL product
candidates through the clinic, David’s strategic approach to drug
development in oncology coupled with his exceptional leadership
skills will be tremendously valuable and we look forward to his
guidance and contributions,” said Stephen T. Isaacs, chairman,
president and chief executive officer of Aduro. “On behalf of the
Board, shareholders and employees, I would also like to thank and
recognize Frank for his support over the last nine years, which
helped to shape Aduro and its core technologies from our founding
to where we are today. We appreciate Frank’s continued involvement
with Aduro through our Scientific Advisory Board.”
“Aduro is well-positioned with a leadership position in the
STING and APRIL pathways, multiple collaboration partnerships and a
strong balance sheet,” commented Dr. Mack. “I’m thrilled to begin
working with the Aduro team at this important time as the company
focuses on the opportunities for its STING and APRIL programs to
positively impact patient treatment in cancer, autoimmune and
inflammatory diseases.”
Dr. Mack brings more than 25 years of senior leadership
experience in biotechnology. Prior to co-founding PMV
Pharmaceuticals, Dr. Mack was a general partner at Alta Partners
from 2002 to 2013. His first investment was Angiosyn (acquired by
Pfizer in 2005), where he was a director and CEO. Prior to Alta,
Dr. Mack co-founded and served as vice president of Genomics
Research at Eos Biotechnology (acquired by Protein Design Labs in
2003). From 1994 to 1997, he served at Affymetrix as head of Cancer
Biology where he oversaw the development and application of DNA
array technology in the areas of oncology and inflammation. Dr.
Mack was also a pivotal member of the Polymerase Chain Reaction
(PCR) Invention Group at Cetus (now Novartis) in the mid 1980s. He
has co-authored more than 30 scientific articles and reviews,
including papers published in Cell, Science, and Nature, and is an
inventor on 26 issued US patents. Dr. Mack was an American Cancer
Society postdoctoral fellow in microbiology and immunology at
Stanford University School of Medicine. He received his Ph.D. from
the University of Chicago, where he was a Howard Hughes fellow in
molecular genetics and cell biology, and he received a B.A. in
molecular biology from the University of California, Berkeley. Dr.
Mack has served on the Boards of Directors of numerous
biotechnology companies including Angiosyn, Aerie Pharmaceuticals,
Ceregene, Proacta Therapeutics, aTyr Pharmaceuticals, Pathwork
Diagnostics, Silence Therapeutics, and Sutro Biopharma. He is
currently on the Scientific Advisory Board of City of Hope.
Dr. McCormick has served as a member of Aduro’s Board of
Directors since 2010 and has joined Aduro’s Scientific Advisory
Board. Dr. McCormick is Director of the University of California,
San Francisco (UCSF) Helen Diller Family Comprehensive Cancer
Center, and Associate Dean of the UCSF School of Medicine. He has
been a Fellow of the Royal Society, a society for science since
1996.
About Aduro Aduro Biotech, Inc. is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of therapies that are designed to
harness the body's natural immune system for the treatment of
patients with challenging diseases. Aduro’s product candidates in
the Stimulator of Interferon Genes (STING) and A Proliferation
Inducing Ligand (APRIL) pathways are being investigated in cancer,
autoimmune and inflammatory diseases. ADU-S100 (MIW815), which
potentially activates the intracellular STING receptor for a potent
tumor-specific immune response, is being evaluated in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
BION-1301, a fully blocking monoclonal antibody that blocks APRIL
binding to both the BCMA and TACI receptors, is being evaluated in
multiple myeloma and as a potential treatment for IgA nephropathy.
Aduro is collaborating with a number of leading global
pharmaceutical companies to help expand and drive its product
pipeline. For more information, please
visit www.aduro.com.
Cautionary Note on Forward-Looking
Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, the potential for our STING and
APRIL programs for the treatment of cancer, autoimmune and
inflammatory diseases and the value and contributions that Dr. Mack
will provide as a director and Dr. McCormick’s role on our
Scientific Advisory Board. In some cases, you can identify these
statements by forward-looking words such as “may,” “will,”
“continue,” “anticipate,” “intend,” “could,” “project,” “expect” or
the negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, early or preliminary clinical trial
results may not be predictive of future results, our history of net
operating losses and uncertainty regarding our ability to achieve
profitability, our ability to develop and commercialize our product
candidates, our ability to use and expand our technologies to build
a pipeline of product candidates, our ability to obtain and
maintain regulatory approval of our product candidates, our ability
to operate in a competitive industry and compete successfully
against competitors that have greater resources than we do, our
reliance on third parties, and our ability to obtain and adequately
protect intellectual property rights for our product
candidates. We discuss many of these risks in greater detail
under the heading “Risk Factors” contained in our quarterly report
on Form 10-Q for the quarter ended September 30, 2018, which is on
file with the Securities and Exchange Commission. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Investor
Relations Contact: |
|
Media
Contact: |
Noopur
Liffick |
|
Aljanae
Reynolds |
510-809-2465 |
|
510-809-2452 |
investors@aduro.com |
|
press@aduro.com |
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Jul 2023 to Jul 2024